This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Barclays' 30 Best Stock Picks for 2011

6. Teva Pharmaceutical (TEVA - Get Report) is the leader in generic pharmaceuticals and makes branded drugs.

Barclays views earnings visibility as high and sees limited downside in Teva shares. Currently, major concern stems from the potential generic competition for Teva's branded multiple sclerosis drug Copaxone. However, Barclays doesn't expect substantial generic competition until 2014 or perhaps even later.

Barclays' admittedly conservative $73 target implies a one-year gain of 42% in Teva's stock, which currently sells for a forward earnings multiple of 9.7 and a book value multiple of 2.1, 19% and 58% discounts to pharmaceutical peer averages. Around 81% of analysts rate it "buy", signaling optimism.

5. JPMorgan (JPM - Get Report) is a diversified financial-services company, with commercial and retail units.

According to Barclays, JPMorgan "holds a top three position in each of its six key businesses." Of note: Its investment bank, which accounts for 22% of sales, has a top two position in the ever-important emerging markets. Barclays expects the bank to boost its dividend and amplify share repurchases in 2011. Potential upside catalysts include loan growth and a pop in capital-markets businesses.

Ongoing difficulty in mortgages and credit cards is a concern. JPMorgan trades at eight-times Barclays's 2011 earnings projection, less than the historical average of 13. It is cheap based on cash flow.

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WFR $0.00 0.00%
DV $17.35 0.00%
JPM $63.20 0.00%
IVZ $31.01 0.00%
TEVA $54.45 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs